glp 1 libido When GLP-1s Change Patients' Libido: What to Know GLP-1's have been a powerful

Popularity spiked dramatically following Wegovy's approval, with prescriptions doubling in 2022 and again in 2023

Not only did patients lose weight as expected -- an average of 4.4 kg from baseline -- but triglyceride and low-density lipoprotein (LDL) cholesterol levels also declined significantly

With the FDAs approval of tirzepatide for obstructive sleep apnea, this treatment offers a promising new option for individuals with obesity-related sleep apnea who struggle with traditional therapies

The insurer spent $300 million on GLP-1 medications in 2024, 50% higher than in 2023

Struggling to Lose Weight on Obesity Drugs

[4] A major double-blind study (17,604 participants) showed semaglutide (Wegovy) reduces major adverse cardiovascular events by 20% in adults with overweight/obesity and established cardiovascular disease, but without diabetes